Navigation Links
ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results
Date:11/2/2010

05.4

73.3

44%License revenue

--

2.9

--

--

3.1

--Total revenues

$42.0

$32.0

31%

$105.4

$76.4

38%Net revenues for the third quarter ended September 30, 2010, were $42.0 million, an increase of 31% over the third quarter of 2009.  Net revenue growth was driven primarily by strong demand for XIBROM™ and BEPREVE, supported by revenue increases in VITRASE®.  In the third quarter of 2009, ISTA recognized $2.9 million of previously deferred license revenue associated with the termination of a supply agreement.  Excluding the recognition of deferred license revenue in 2009, net product revenues increased 44% in third quarter 2010 over third quarter 2009.

Gross margin for the third quarter ended September 30, 2010, was 77%, or $32.3 million, as compared to 77%, or $24.7 million, for the same period in 2009.  Product gross margin was 77% for the third quarter 2010 and was 75% for the third quarter ended September 30, 2009.  Product gross margin improved due to increased sales of our higher gross margin products, XIBROM and BEPREVE.

Research and development (R&D) expenses for the quarter ended September 30, 2010, were $7.9 million, as compared to $6.3 million during the corresponding period of 2009.  The increase over the prior-year period was due primarily to the timing, initiation and completion of clinical trials.  ISTA initiated its Phase 1/2 clinical program for bepotastine nasal spray in July and its REMURA Phase 3 clinical program for dry eye disease in September.

Selling, general, and administrative, or SG&A, expenses for the quarter ended September 30, 2010, increased to $19.6 million from $13.2 million for the corresponding period in 2009.  The increase over the prior-year period reflects the addition of approximately 65 new sales representatives and related corporate new hires earlier in the
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. DUSA Pharmaceuticals, Inc.® to Host Third Quarter 2010 Corporate Highlights and Financial Results Conference Call
2. Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants
3. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
4. Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors
5. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
6. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
7. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
8. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2010 Financial Results on November 5, 2010
9. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
10. VIDEO from thenewsmarket.com and Roche Pharmaceuticals: MabThera Approved in Europe for First Line Maintenance Treatment of Follicular Lymphoma, a Common Type of Blood Cancer
11. MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX™ in FREEDOM-301 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Ardelyx, Inc. (NASDAQ: ARDX ), a clinical-stage ... today announced that the Company will host its inaugural ... 1:00 pm EDT in New York City ... team will present an overview of the Company,s pipeline ... Phase 2b clinical trials for the treatment of patients ...
(Date:6/30/2015)... Fla. , June 30, 2015  July 4 th ... declaration of independence, and the spirit and people behind it. ... Foundation has partnered with USA Medical ... help increase funding for programs that empower independence for our ... country, and help more people afford their prescriptions. ...
(Date:6/30/2015)... WAYNE, Pa. , June 30, 2015 ... ("Egalet"), a fully integrated specialty pharmaceutical company ... pain treatments, today announced top-line results from ... study of Egalet-002, an abuse-deterrent, extended-release, oral ... for the management of pain severe enough ...
Breaking Medicine Technology:Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2Hope For Heroes and USA Medical Card Make a Difference for Our Nation's Heroes 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
... Targeting Pro-Inflammatory,Protein -, GAITHERSBURG, Md., April 18, ... publication of preclinical,study data demonstrating a role ... nuclear DNA-binding protein, in the pathology,of systemic ... or lupus) and rheumatoid arthritis. Data to ...
... RIDGE, N.J., April 19, 2007 /PRNewswire-FirstCall/ --,VioQuest ... focused on acquiring, developing and,commercializing targeted cancer ... VQD- 002, a direct inhibitor of Akt,activation ... tumors.,Pre-clinical data was presented in a poster ...
Cached Medicine Technology:MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 2MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 2VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 3VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 4VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting 5
(Date:6/30/2015)... ... 2015 , ... Carey Danis & Lowe comments on a new ... Virginia federal court. The court document outlined the judge’s plan to consolidate 26 vaginal ... Carey Danis & Lowe is a personal injury law firm with headquarters in St. ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reputable source of ... native of Detroit, MI, Kid Rock, is hitting the road again this summer in what ... and hip hop superstar kicked off his summer tour this year at the XFINITY Theatre ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... Texas have launched a ‘responsive design’ website to inform potential sinus surgery patients ... them. , The website includes information about a wide variety of ENT issues ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... pleased to announce it’s own Debby Mann, CPC, RCC, ROCC, Coding Documentation and ... Summit with the Special Recognition Award for her contribution to the RBMA Coding ...
(Date:6/30/2015)... ... June 30, 2015 , ... Today, Grand ... “Grand Terrace Health Care Center.” Each year, Medicare ranks care centers around the ... best facility for their needs. Grand Terrace prides itself on quality in each ...
Breaking Medicine News(10 mins):Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 2Health News:Carey Danis & Lowe Comments on New Pretrial Order in Vaginal Mesh Lawsuit 3Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2
... of Pennsylvania School of Medicine have created the first ... a mutation known to produce disease in people, an ... in the October issue of Human Molecular Genetics. ... of vision loss in elderly people, affecting more than ...
... Oct. 9 The following was released,today by the ... MR. TENPAS: Good morning. I am Ronald ... Natural Resources Division here at the,Department of Justice. ... administrator for Enforcement and Compliance Assurance., We ...
... wane over time, study finds , , TUESDAY, Oct. 9 ... who,ve lost weight keep it off, new research suggests. ... of the maintenance programs wears off over time, suggesting ... maintain healthier lifestyles. , "We were excited ...
... a potentially novel way to fight colorectal cancer using ... cancer cells, unlike current treatments that bind to the ... cause unwanted side effects. , In laboratory studies ... system proved able to specifically target colon cancer cells, ...
... NEW YORK, Oct. 9 Highlands Acquisition Corp.,(Amex: HIA.U), ... public offering (the "IPO") of 12,000,000 units. Each unit ... which entitles the holder to,purchase one share of common ... $10.00 per unit, generating gross proceeds of $120,000,000 to ...
... age of 12 currently drink alcohol, according to a ... Services Administration. While the majority of people who drink ... in the expression of violence. , By far the ... violent behavior involves alcohol, says Dr. Jeff Kretschmar, a ...
Cached Medicine News:Health News:Model to study age-related macular degeneration could pave way for better treatment 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 3Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 4Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 5Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 6Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 7Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 8Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 9Health News:Maintenance Treatment Helps Kids Keep Weight Off 2Health News:Maintenance Treatment Helps Kids Keep Weight Off 3Health News:Maintenance Treatment Helps Kids Keep Weight Off 4Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Highlands Acquisition Corp. Completes Initial Public Offering 2Health News:Highlands Acquisition Corp. Completes Initial Public Offering 3
The CKMB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase MB isoenzyme activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: